BioCentury | Apr 7, 2014
Clinical News

Thyrogen thyrotropin alpha regulatory update

...Sanofi's Genzyme Corp. subsidiary said FDA approved a label expansion for Thyrogen thyrotropin alfa to include...
...in post-thyroidectomy patients maintained on hormone suppression therapy. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Thyrogen thyrotropin alpha...
BioCentury | Dec 17, 2012
Clinical News

Thyrogen thyrotropin alpha regulatory update

...Sanofi's Genzyme Corp. subsidiary said the European Commission approved a label expansion for Thyrogen thyrotropin alfa...
...in post-thyroidectomy patients maintained on hormone suppression therapy. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Thyrogen thyrotropin alpha...
BioCentury | Nov 19, 2012
Company News

Sanofi sales and marketing update

...cancer treatment Thyrogen thyrotropin alfa have returned to normal. Genzyme had experienced supply constraints for Thyrogen...
...said supply had been restricted due to low inventory and lead time necessary to create Thyrogen...
...stimulating hormone. Late last year, Genzyme notified FDA it had resumed intermittent global shipments of Thyrogen...
BioCentury | Nov 14, 2012
Company News

Thyrogen supply restored to normal

...Genzyme Corp. said global supply levels of thyroid cancer treatment Thyrogen thyrotropin alfa have returned to...
...have returned to normal. The subsidiary of Sanofi (Euronext:SAN; NYSE:SNY) had experienced supply constraints for Thyrogen...
BioCentury | Oct 29, 2012
Clinical News

Thyrogen thyrotropin alpha regulatory update

...treatment Thyrogen thyrotropin alpha from Sanofi's Genzyme Corp. subsidiary to include a radioiodine dose range. Specifically, Thyrogen...
...in post-thyroidectomy patients maintained on hormone suppression therapy. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Thyrogen thyrotropin alpha...
BioCentury | Dec 5, 2011
Clinical News

Thyrogen thyrotropin alpha regulatory update

...Thyrogen thyrotropin alfa but that supply will continue to be restricted until 2012. Product: Thyrogen thyrotropin alpha...
...the committee that intermittent shipments of Thyrogen would resume but that the supply shortage for Thyrogen...
...several factors, including: ongoing constraints in Thyrogen manufacturing capacity; longer timelines to manufacture and release Thyrogen...
BioCentury | Aug 1, 2011
Clinical News

Thyrogen thyrotropin alpha regulatory update

...Sanofi's Genzyme Corp. subsidiary notified the committee that the supply shortage for thyroid cancer treatment Thyrogen...
...not be effective. Product: Thyrogen thyrotropin alpha Business: Cancer In July, Genzyme said intermittent shipments of Thyrogen...
...several factors, including: ongoing constraints in Thyrogen manufacturing capacity; longer timelines to manufacture and release Thyrogen...
BioCentury | Mar 21, 2011
Finance

Highlights of weekly biotech stock moves

...will be able to meet only about 45% of European demand for thyroid cancer treatment Thyrogen...
...of a manufacturing issue. Genzyme said it identified a processing problem in a batch of Thyrogen...
BioCentury | Mar 21, 2011
Clinical News

Thyrogen thyrotropin alpha regulatory update

...will only be able to meet about 45% of European demand for thyroid cancer treatment Thyrogen...
...not be effective. Thyrogen use for other patients should be delayed until the supply of Thyrogen...
...acquired by sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France). Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass. Product: Thyrogen thyrotropin alpha...
BioCentury | Mar 19, 2011
Company News

Genzyme's Thyrogen facing supply shortage

...will be able to meet only about 45% of European demand for thyroid cancer treatment Thyrogen...
...thyrotropin alfa until July. Genzyme said it identified a processing problem in a batch of Thyrogen...
...not be effective. Thyrogen use for other patients should be delayed until the supply of Thyrogen...
Items per page:
1 - 10 of 78